DRAP REGISTERED MEDICAL DEVICE
Cingal injection (Cross-linked sodium hyaluronate Triamcinolone hexacetonide) [4ml] is registered with DRAP under number MDIR-0004493 as a Class D (high risk) medical device, imported. The listed holder is Bionta Pharma. It is listed as valid until 5 Jan 2028.
Screening result
MDIR-0004493 · the class is taken from DRAP's list for this number
DRAP registered Class B/C/D list, 28 Aug 2025
ELI-00367
| Device | Cingal injection (Cross-linked sodium hyaluronate Triamcinolone hexacetonide) [4ml] |
|---|---|
| Class | D |
| Listed holder | Bionta Pharma |
| Holder address | Suit No. A-10, Plot No. B-10, Gulshan-e-Iqbal Karachi |
| Manufacturing site | M/s Anika Therapeutics, Inc. 32 Wiggins Avenue, Bedford MA, 01730, USA. |
| Issued | 6 Jan 2023 |
| Renewal date | 5 Jan 2028 |
| Licence | ELI-00367 |
Specifications
No supplier specifications yet.
Supplier of this device? Add specifications (free during launch)
Sign in or create a free account to add specifications.
Screened 5 Oct 2026, 15:53 (Pakistan time). A screening aid, not an official DRAP verification.
More devices from this holder
Other DRAP registrations and enlistments listed for the same company.
| MDIR-0003713 | Mosovisc (hyaluronic acid) [4ml Volume] | Class D |
| MDIR-0004494 | Orthovisc (hyaluronic acid) [15mg/ml, 2ml Volume 15mg/ml, 1ml Volume] | Class D |
Corrections
Is something on this page wrong? Report a correction
Corrections are checked against the evidence before anything changes on this page.
Screen another number
Source: DRAP's published provisional lists. A screening aid, not an official DRAP verification; confirm with DRAP and the supplier's original documents.